Re: eGFR and Cognition: Correction:
in response to
by
posted on
Nov 23, 2019 02:47PM
Bear, you are correct, as always... I misread the population at the top of Cabel's question , and was referring to phase II date with my corrections :\ My apologies Cabel!
Throughout the total BETonMace (Phase III study) population; results are so far not in the direction expected, however, I agree with Bear it is clinically meaningless... most people in this study started with a normal eGFR and ended with a normal eGFR.
And we do not yet have the data to confirm phase II study results for the "sick kidney" population, but hoping:
- that eGFR <60 patients will have eGFR go up significantly in the treated group and down/at least not up, in the placebo group... to show APABETALONE both decreases MACE (already proven ) and increases eGFR in sick patients... with statistical significance.
That's a good drug even before MoCA improvement, but here's hoping for all !